Safety Exposure‐Response Analysis for Daclatasvir, Asunaprevir, and Beclabuvir Combinations in HCV‐Infected Subjects

The combination regimen of daclatasvir, asunaprevir, and beclabuvir has been developed for the treatment of hepatitis C virus infection. The objectives of this analysis were to characterize the relationship between the exposures of the daclatasvir, asunaprevir, and beclabuvir regimen and liver‐relat...

Descripción completa

Detalles Bibliográficos
Autores principales: Osawa, Mayu, Ueno, Takayo, Shiozaki, Tomomi, Li, Hanbin, Garimella, Tushar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6590348/
https://www.ncbi.nlm.nih.gov/pubmed/30566237
http://dx.doi.org/10.1002/jcph.1347

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6590348/
https://www.ncbi.nlm.nih.gov/pubmed/30566237
http://dx.doi.org/10.1002/jcph.1347

Ejemplares similares